Ad Header



The Pulse of the Pharmaceutical Industry

AstraZeneca, Chi-Med take kidney cancer drug into final testing

Written by: | | Dated: Thursday, June 29th, 2017


AstraZeneca and Hutchison China MediTech said on Thursday they had initiated a global late-stage clinical trial of the experimental drug savolitinib in a relatively rare type of kidney cancer.

The launch triggers a $5 million payment from AstraZeneca to the Shanghai-based drugmaker, which is listed in London and is known as Chi-Med. The move underscores Chi-Med’s drive to bring modern Chinese drugs to the international market.

The Phase III study will test savolitinib in c-MET-driven papillary renal cell carcinoma.


(Reporting by Ben Hirschler, editing by David Evans)


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation